Shares of Artiva Biotherapeutics Inc. (ARTV) are down nearly 45% from their 52-week high of $14.53, recorded this April, and trade around $8.
This clinical-stage biotechnology company is developing a deep B-cell-depleting therapy for patients with refractory rheumatoid arthritis (RA) who have experienced inadequate response or treatment failure with two or more biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com